Radiotherapy for invasive breast cancer: Guidelines for clinical practice from the French expert review board of Nice/Saint-Paul de Vence

Critical Reviews in Oncology/Hematology

Volumn 79, Issue 2, 2011, Pages 91-102

  Belkacemi Y ^a   Fourquet, A ^b   Cutuli, B ^c   Bourgier, C ^d   Hery, M ^f   Ganem, G ^g   Marsiglia, H ^d,e   Namer, M ^h   Gligorov, J ⁱ   Azria, D ^j  

^a HENRI MONDOR HOSPITAL   (France)

^b INSTITUT CURIE   (France)

^c Clinique de Courlancy   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e UNIVERSITY OF FLORENCE   (Italy)

^f Centre Hospitalier Princesse Grace Monaco   (France)

^g CENTRE JEAN BERNARD   (France)

^h Centre Azureen de Cancerologie   (France)

ⁱ HÔPITAL TENON   (France)

^j CENTRE VAL D AURELLE   (France)

more..

Author keywords

Breast cancer; Guidelines; Radiotherapy; Saint Paul de Vence guidelines

Indexed keywords

ANASTROZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EXEMESTANE; LETROZOLE; METHOTREXATE; MITOXANTRONE; PACLITAXEL; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; COMORBIDITY; ESOPHAGUS DISEASE; EVIDENCE BASED MEDICINE; HUMAN; LIFE EXPECTANCY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE CARE; PRACTICE GUIDELINE; RADIATION DOSE; RADIATION PNEUMONIA; REVIEW; SYSTEMATIC REVIEW; TREATMENT INDICATION;

AGE FACTORS; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DATABASES, FACTUAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; NEOPLASM INVASIVENESS; RADIATION DOSAGE; RADIATION ONCOLOGY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEX FACTORS; TAMOXIFEN;

EID: 79960185275     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.06.002     Document Type: Review

References (75)

1. Belot A., Grosclaude P., Bossard N., et al. Cancer incidence and mortality in France over the period 1980-2005. Rev Epidemiol Sante Publique 2008, 56:159-175.
2. Gligorov J., Krakowski I., Luporsi E., Namer M. Recommandations pour la Pratique Clinique: Nice-Saint-Paul-de-Vence 2009. «cancers du sein». Oncologie 2009, 11:495-610.
3. Bellon J.R., Come S.E., Gelman R.S., et al. Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial. J Clin Oncol 2005, 23:1934-1940.
4. EBCTCG Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005, 366:2087-2106.
5. Whelan T., Pignol J.P., Levine M.N., et al. Long term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010, 362:513-520.
6. Yarnold J., Ashton A., Bliss J., et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiother Oncol 2005, 75:9-17.
7. START Trialists' Group, Bentzen S.M., Agrawal R.K., Aird E.G., et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 2008, 371:1098-1107.
8. Romestaing P., Lehingue Y., Carrie C., et al. Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. J Clin Oncol 1997, 15:963-968.
9. Romestaing P., Belot A., Hennequin C., et al. Ten-year results of a randomized trial of internal mammary chain irradiation after mastectomy. Int J Radiat Oncol Biol Phys 2009, 75(Suppl. 3):S1. [Abstract 1].
10. Bartelink H., Horiot J.C., Poortmans P., et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 2001, 345:1378-1387.
11. Bartelink H., Horiot J.C., Poortmans P.M., et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol 2007, 25:3259-3265.
12. Polgar C., Fodor J., Orosz Z., et al. Electron and high-dose-rate brachytherapy boost in the conservative treatment of stage I-II breast cancer first results of the randomized Budapest boost trial. Strahlenther Onkol 2002, 178:615-623.
13. Overgaard M., Hensen P.S., Overgaard J., et al. Post operative radiotherapy in high-risk premenopausal women with breast canecr who receive adjuvant chemotherapy: Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997, 337:949-955.
14. Overgaard M., Hensen P.S., Overgaard J., et al. Post operative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomized Trial. Lancet 1999, 353:1641-1648.
15. Ragaz J., Olivotto I.A., Spinelli J.J., et al. Locoregional radiation therapy in patients with high risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst 2005, 97:116-126.
16. Nielsen H.M., Overgaard M., Grau C., et al. Study of failure pattern among high-risk breast cancer patients with or witout postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danich Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. J Clin Oncol 2006, 24:2268-2275.
17. Wallgren A., Bernier J., Gelbre R.D., et al. Timing of radiotherapy and chemotherapy following breast-conservative surgery for patients with node-positive breast cancer. Int J Radiat Oncol Biol Phys 1996, 35:649-659.
18. Jagsi R., Raad R.A., Goldberg S., et al. Locoregional recurrence rates and prognostic factors for failure in node-negative patients treated with mastectomy: implications for postmastectomy radiation. Int J Radiat Oncol Biol Phys 2005, 62:1035-1039.
19. Veronesi U., Cascinelli N., Bufalino R., et al. Risk of internal mammary lymph node metastases and its relevance on prognosis of breast cancer patients. Ann Surg 1983, 198:681-684.
20. Pierce L.J., Hutchins L.F., Green S.R., et al. Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. J Clin Oncol 2005, 23:24-29.
21. Ahn P., Vu H.T., Lanin D., et al. Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates. J Clin Oncol 2005, 23:17-23.
22. Harris E.R., Christensen V.J., Hwang W.T., et al. Impact of concurrent versus sequential tamoxifen with radiation therapy in early-stage breast cancer patients undergoing breast conservation treatment. J Clin Oncol 2005, 23:11-16.
23. Azria D., Belkacemi Y., Romieu G., et al. Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial. Lancet Oncol 2010, 11:258-265.
24. Arcangeli G., Pinnaro P., Rambone R., et al. A phase III randomized study on the sequence of radiotherapy and chemotherapy in the conservative management of early-stage breast cancer. Int J Radiat Oncol Biol Phys 2006, 64:161-167.
25. Rouëssé J., De la Lande B., Bertheault-Cvitkovic F., et al. A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results. Int J Radiat Oncol Biol Phys 2006, 64:1072-1080.
26. Toledano A., Azria D., Garaud P., et al. Concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer. Final clinical results of the ARCOSEIN phase III randomized trial. J Clin Oncol 2007, 25:405-410.
27. Burstein H.J., Bellon J.R., Galper S., et al. Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer. Int J Radiat Oncol Biol Phys 2006, 64:496-504.
28. Taghian A.G., Assaad S.I., Niemierko A., et al. Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel. J Natl Cancer Inst. 2001, 93:1806-1811.
29. Joensuu H., Kellokumpu-Lehtinen P.L., Bono P., et al. Trastuzumab in combination with docetaxel or vinorelbine as adjuvat treatment of breast cancer: the FinHer trial. N Engl J Med 2006, 354:809-820.
30. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2 positive breast cancer. N Engl J Med 2005, 353:1673-1684.
31. Piccart-Gebhart M., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy for HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672.
32. Benk V., Levinton C., Fortin P.R., et al. Effect of delay in initiating radiotherapy for patients with early stage breast cancer: results of a natural experiment. Int J Radiat Oncol Biol Phys 1999, 45:305-306.
33. Mackillop W.J., Bates J.H.T., Withers H.R. The effect of delay in treatment on local control by radiotherapy. Int J Radiat Oncol Biol Phys 1996, 34:243-250.
34. Tsoutsou P., Koukourakis M.I., Azria D., Belkacemi Y. Optimal timing for adjuvant radiation therapy in breast cancer. A comprehensive review and perspectives. Crit Rev Oncol Hematol 2009, 71:102-116.
35. Buchholz T., Tucker S., Erwin J., et al. Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy. J Clin Oncol 2001, 19:2240-2246.
36. Truong P.T., Bernstein V., Lesperance M., et al. Radiotherapy omission after breast-conserving surgery is associated with reduced breast cancer-specific survival in elderly women with breast cancer. Am J Surg 2006, 191:749-755.
37. Sanghani M., Balk E., Cady B., Wazer D. Predicting the risk of local recurrence in patients with breast cancer: an approach to a new computer-based predictive tool. Am J Clin Oncol 2007, 30:473-480.
38. Nguyen P.L., Taghian A.G., Katz M.S., et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 2008, 26:2373-2378.
39. Kyndi M., Sørensen F.B., Knudsen H., et al. Danish Breast Cancer Cooperative Group. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol 2008, 26:1419-1426.
40. Haffty B.G., Yang Q., Reiss M., et al. Loco-regional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006, 24:5652-5657.
41. Parikh R.R., Yang Q., Higgins S.A., Haffty B.G. Outcomes in young women with breast cancer of triple-negative phenotype: the prognostic significance of CK19 expression. Int J Radiat Oncol Biol Phys 2008, 70:35-42.
42. Belkacémi Y., Penault-Llorca F., Gligorov J., Azria D. The use of breast cancer subtype classification to predict local and distant recurrence. A review. Cancer Radiother 2008, 12:577-583.
43. Cutuli B., De Lafontan B., Vitali E., et al. Breast conserving treatment (BCT) for stage I-II breast cancer in elderly women: analysis of 927 cases. Crit Rev Oncol Hematol 2009, 71:79-88.
44. Kirova Y.M., Pena P.C., Hijal T., et al. Improving the definition of tumor bed boost with the use of surgical clips and image registration in breast cancer patients. Int J Radiat Oncol Biol Phys 2010, [Epub ahead of print].
45. Dzhugashvili M., Pichenot C., Dunant A., et al. Surgical clips assist in the visualization of the lumpectomy cavity in three-dimensional conformal accelerated partial-breast irradiation. Int J Radiat Oncol Biol Phys 2010, 76:1320-1324.
46. Ceilley E., Jagsi R., Goldberg S., et al. Radiotherapy for invasive breast cancer in North America and Europe: results of a survey. Int J Radiat Oncol Biol Phys 2005, 61:365-373.
47. Recht A., Edge S.B., Solin L.J., et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001, 19:1539-1569.
48. Taghian A.G., Jeong J.-H., Mamounas E.P., et al. Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5cm or larger treated by mastectomy, with or without systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials. J Clin Oncol 2006, 24:3927-3932.
49. Taghian A., Jagsi R., Makris A., et al. Results of a survey regarding irradiation of internal mammary chain in patients with breast cancer: practice is culture driven rather than evidence based. Int J Radiat Oncol Biol Phys 2004, 60:706-714.
50. Huang O., Wang L., Shen K., et al. Breast cancer subpopulation with high risk of internal mammary lymph nodes metastasis: analysis of 2,269 Chinese breast cancer patients treated with extended radical mastectomy. Breast Cancer Res Treat 2008, 107:379-387.
51. Wazer D.E., Di Petrillo T., Schmidt-Ullrich R., et al. Factors influencing cosmetic outcome and complication risk after conserving surgery and radiotherapy for early-stage breast carcinoma. J Clin Oncol 1992, 10:356-363.
52. Taylor M.E., Perez C.A., Halverson K.J., et al. Factors influencing cosmetic results after conservation therapy for breast cancer. Int J Radiat Oncol Biol Phys 1995, 31:753-764.
53. Fowble B., Fein D.A., Hanlon A.L., et al. The impact of tamoxifen on breast recurrence, cosmesis, complications, and survival in estrogen receptor-positive early-stage breast cancer. Int J Radiat Oncol Biol Phys 1996, 35:669-677.
54. Azria D., Gourgou S., Sozzi W.J., et al. Concomitant use of tamoxifen with radiotherapy enhances subcutaneous breast fibrosis in hypersensitive patients. Br J Cancer 2004, 91:1251-1260.
55. Bentzen S.M., Skoczylas J.Z., Overgaard M., et al. Radiotherapy-related lung fibrosis enhanced by tamoxifen. J Natl Cancer Inst 1996, 88:918-922.
56. Koc M., Polat P., Suma S. Effects of tamoxifen on pulmonary fibrosis after cobalt-60 radiotherapy in breast cancer patients. Radiother Oncol 2002, 64:171-175.
57. Kesisis G., Makris A., Miles D. Update on the use of aromatase inhibitors in early-stage breast cancer. Breast Cancer Res 2009, 11(5):211.
58. Recht A., Come S.E., Gelman R.S., et al. Integration of conservative surgery, radiotherapy, and chemotherapy for the treatment of early-stage, node-positive breast cancer: sequencing, timing, and outcome. J Clin Oncol 1993, 11:191-193.
59. Huang J., Barbera L., Brouwers M., et al. Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review. J Clin Oncol 2003, 21:555-563.
60. Recht A., Come S.E., Henderson I.C., et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med 1996, 334:1356-1361.
61. Coates A. International Breast Cancer Study Group trials. Recent results. Cancer Res 1998, 152:429-440.
62. Belkacemi Y., Gligorov J., Ozsahin, et al. Adjuvant trastuzumab and radiation therapy in patients with HER2 breast cancer: a French multicenter prospective study. Ann Oncol 2008, 19:1110-1116.
63. Halyard M.Y., Pisansky T.M., Dueck A.C., et al. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol 2009, 27:2638-2644.
64. Kirova Y.M., Caussa L., Granger B., et al. Monocentric evaluation of the skin and cardiac toxicities of the concomitant administration of trastuzumab and radiotherapy. Cancer Radiother 2009, 13:276-280.
65. Shaffer R., Tyldesley S., Rolles M., et al. Acute cardiotoxicity with concurrent trastuzumaband radiotherapy including internal mammary chain nodes: a retrospective single-institution study. Radiother Oncol 2009, 90:122-126.
66. Belkacemi Y., Gligorov J. Concurrent trastuzumab-Internal mammary irradiation for HER2 positive breast cancer: " It hurts to be on the cutting edge" Radiother Oncol 2009.
67. Bellon J.R., Gover M.T., Burstein H.J., et al. Concurrent trastuzumab and radiation therapy (RT) in the adjuvant treatment of breast cancer. Proc. Int J Radiat Oncol Biol Phys 2005, [Abstract 91].
68. Harcourt D.M., Rumsey N.J., Ambler N.R., et al. The psychological effect of mastectomy with or without breast reconstruction: a prospective, multicenter study. Plast Reconstr Surg 2003, 111:1060-1068.
69. Cordeiro P.G., Pusic A.L., Disa J.J., et al. Irradiation after immediate tissue expander/implant breast reconstruction: outcomes, complications, aesthetic results, and satisfaction among 156 patients. Plast Reconstr Surg 2004, 113:877-881.
70. Jhaveri J.D., Rush S.C., Kostroff K., et al. Clinical outcomes of postmastectomy radiation therapy after immediate breast reconstruction. Int J Radiat Oncol Biol Phys 2008, 72:859-865.
71. Mehta V.K., Goffinet D. Postmastectomy radiation therapy after TRAM flap breast reconstruction. Breast J 2004, 10:118-122.
72. Hebert-Croteau N., Freeman C.R., Latreille J., et al. A population-based study of the impact of delaying radiotherapy after conservative surgery for breast cancer. Breast Cancer Res Treat 2004, 88:187-196.
73. Hershman D.L., Wang X., McBride R., et al. Delay in initiating adjuvant radiotherapy following breast conservation surgery and its impact on survival. Int J Radiat Oncol Biol Phys 2006, 65(5):1353-1360.
74. Mikeljevic J.S., Haward R., Johnston C., et al. Trends in postoperative radiotherapy delay and the effect on survival in breast cancer patients treated with conservation surgery. Br J Cancer 2004, 90:1343-1348.
75. Guidelines, minimal requirements and standard of cancer care around the Mediterranean Area: Report from the Collaborative Update ref by: AROME (Association of Radiotherapy and Oncology of the Mediterranean Area) working parties. AROME. Crit Rev Oncol Hematol. 2010 Apr 15. [Epub ahead of print].